[{"address1": "10900 Wilshire Blvd", "address2": "Suite 600", "city": "Los Angeles", "state": "CA", "zip": "90024", "country": "United States", "phone": "310 388 6706", "website": "https://www.chromadex.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 104, "companyOfficers": [{"maxAge": 1, "name": "Mr. Frank Louis Jaksch Jr.", "age": 56, "title": "Co-Founder & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ozan  Pamir C.F.A.", "age": 32, "title": "CFO & Principal Accounting Officer", "yearBorn": 1992, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew  Shao Ph.D.", "title": "Senior Vice President of Global Regulatory & Scientific Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carlos  Lopez", "title": "Senior VP & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michiko  Kelley", "title": "Chief Marketing Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kendall  Knysch", "title": "Head of Media Relations & Partnerships", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 6, "compensationRisk": 6, "shareHolderRightsRisk": 3, "overallRisk": 4, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.94, "open": 7.91, "dayLow": 7.745, "dayHigh": 7.92, "regularMarketPreviousClose": 7.94, "regularMarketOpen": 7.91, "regularMarketDayLow": 7.745, "regularMarketDayHigh": 7.92, "payoutRatio": 0.0, "beta": 2.213, "trailingPE": 71.545456, "forwardPE": 40.01627, "volume": 541672, "regularMarketVolume": 541672, "averageVolume": 822171, "averageVolume10days": 565233, "averageDailyVolume10Day": 565233, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 611895616, "fiftyTwoWeekLow": 2.305, "fiftyTwoWeekHigh": 9.18, "priceToSalesTrailing12Months": 6.1437154, "fiftyDayAverage": 6.4274, "twoHundredDayAverage": 4.882875, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 561224064, "profitMargins": 0.08585, "floatShares": 50839576, "sharesOutstanding": 77750400, "sharesShort": 2105794, "sharesShortPriorMonth": 2112969, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.0272, "heldPercentInsiders": 0.34792, "heldPercentInstitutions": 0.30001, "shortRatio": 5.91, "shortPercentOfFloat": 0.0418, "impliedSharesOutstanding": 79056304, "bookValue": 0.595, "priceToBook": 13.22689, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 61.974, "netIncomeToCommon": 8550000, "trailingEps": 0.11, "forwardEps": 0.12, "lastSplitFactor": "1:3", "lastSplitDate": 1460505600, "enterpriseToRevenue": 5.635, "enterpriseToEbitda": 65.717, "52WeekChange": 0.8753463, "SandP52WeekChange": 0.11469197, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CDXC", "underlyingSymbol": "CDXC", "shortName": "ChromaDex Corporation", "longName": "Niagen Bioscience, Inc.", "firstTradeDateEpochUtc": 1214314200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "77342014-e7f0-3894-9d34-bbc3f6ead2f8", "messageBoardId": "finmb_5034211", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.87, "targetHighPrice": 12.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.82, "targetMedianPrice": 8.1, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 44508000, "totalCashPerShare": 0.571, "ebitda": 8540000, "totalDebt": 2651000, "quickRatio": 2.963, "currentRatio": 3.572, "totalRevenue": 99597000, "debtToEquity": 5.751, "revenuePerShare": 1.312, "returnOnAssets": 0.07836, "returnOnEquity": 0.22938, "grossProfits": 61586000, "freeCashflow": 9606750, "operatingCashflow": 12109000, "revenueGrowth": 0.374, "grossMargins": 0.61834997, "ebitdaMargins": 0.08575, "operatingMargins": 0.24415001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]